Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbilical Cord Blood NK Cell Therapy for Pediatric Soft Tissue Sarcoma
NCT06848582Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2024
- Primary completion
- Feb 2026
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of umbilical cord blood-derived NK cells in soft tissue sarcoma (STS), sponsored by Sun Yat-sen University. Primary endpoint: Overall Response Rate at 16 weeks. Started Nov 2024; status: recruiting.
02
Drugs
umbilical cord blood-derived NK cells
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT06848582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06848582.